Press release
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently published Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by Harbour et al.1 The data, from a real-world cohort of 1,297 patients with uveal melanoma (UM), was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City. The findings provide further support for adding Preferentially Expressed Antigen in Melanoma (PRAME) gene expression information to the DecisionDx-UM test result to further refine metastatic risk prediction for patients with UM, which is a rare but aggressive eye cancer. \"This real-world validation of the landmark COOG2.1 study both confirms the long-term performance of the DecisionDx-UM test and affirms the clinical value of PRAME as an adjunct biomarker that may further refine a patient’s metastatic risk when combined with the DecisionDx-UM class result,” said Rebecca Critchley-Thorne, Ph.D., vice-president, research and development, of Castle Biosciences. “This enhanced approach to risk stratification is designed to equip clinicians with more precise information to help guide surveillance strategies and enable more personalized treatment planning with the goal of helping to improve outcomes for patients with UM.” Details regarding Castle’s presentation at ARVO are included below. The abstract may be viewed using the ARVO 2025 mobile meeting planner. Presentation Number 981: PRAME status as a risk modifier of 15-gene expression profile class: Evidence from a real-world cohort of 1297 uveal melanoma patientsPresentation Type: Poster SessionSession Number: 154Session Title: Uveal MelanomaSummary: An ongoing collaboration with the National Cancer Institute’s Surveillance, Epidemiology and End Results (NCI SEER) Program enabled linkage of UM patient records with such patients’ DecisionDx-UM and PRAME test results. In a large, real-world, population-based cohort of patients with UM, this study aimed to validate the findings from the prospective COOG2.1 study, which found that adding the reported expression of the PRAME gene to the DecisionDx-UM class result can further refine risk by subdividing Class 1 a...